Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Margaret Macy

Concepts (237)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Neuroblastoma
14
2026
177
3.040
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2026
2001
1.530
 Why?
Neoplasms
19
2026
2946
1.390
 Why?
Central Nervous System Neoplasms
3
2024
178
1.310
 Why?
Neoplasm Recurrence, Local
14
2026
1166
1.200
 Why?
Sarcoma, Ewing
3
2025
103
1.130
 Why?
Cyclin-Dependent Kinase 4
1
2024
53
0.820
 Why?
Cyclin-Dependent Kinase 6
1
2024
49
0.820
 Why?
Protein Kinase Inhibitors
7
2025
984
0.820
 Why?
Central Nervous System Diseases
1
2024
75
0.760
 Why?
Neoplasms, Second Primary
1
2024
103
0.740
 Why?
Glioma
5
2025
432
0.730
 Why?
Antineoplastic Agents
12
2026
2231
0.730
 Why?
Drug Resistance, Neoplasm
8
2026
889
0.720
 Why?
Piperazines
1
2024
375
0.700
 Why?
Antibodies, Monoclonal, Humanized
5
2022
1005
0.680
 Why?
Glycolipids
1
2021
53
0.670
 Why?
Pyridines
1
2024
610
0.620
 Why?
Child
45
2026
22979
0.610
 Why?
Radiation Injuries
2
2019
149
0.600
 Why?
Indazoles
2
2022
86
0.590
 Why?
Bevacizumab
2
2019
168
0.580
 Why?
Brain Stem Neoplasms
2
2017
87
0.570
 Why?
Benzamides
2
2022
227
0.560
 Why?
Astrocytoma
2
2017
131
0.560
 Why?
Radiotherapy
1
2019
210
0.550
 Why?
Child, Preschool
28
2026
12016
0.540
 Why?
Chemoradiotherapy
2
2017
239
0.540
 Why?
Brain Diseases
1
2019
158
0.530
 Why?
Receptor Protein-Tyrosine Kinases
2
2022
231
0.530
 Why?
Angiogenesis Inhibitors
1
2019
239
0.520
 Why?
Adolescent
33
2026
22825
0.460
 Why?
3-Iodobenzylguanidine
3
2025
13
0.460
 Why?
Prognosis
14
2026
4383
0.440
 Why?
Gangliosides
2
2025
23
0.400
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
2
2026
161
0.390
 Why?
Brain Neoplasms
5
2022
1338
0.390
 Why?
Sarcoma
2
2015
210
0.390
 Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2026
293
0.380
 Why?
Rhabdomyosarcoma
2
2025
65
0.340
 Why?
Sulfonamides
2
2026
596
0.340
 Why?
Piperidines
2
2025
224
0.330
 Why?
Quinazolines
2
2023
266
0.330
 Why?
Neoplasms, Germ Cell and Embryonal
1
2012
76
0.330
 Why?
Topoisomerase II Inhibitors
1
2010
24
0.320
 Why?
Antineoplastic Agents, Immunological
2
2025
200
0.320
 Why?
Biomarkers, Tumor
4
2022
1339
0.320
 Why?
Humans
53
2026
147293
0.310
 Why?
Maximum Tolerated Dose
6
2025
217
0.310
 Why?
Follow-Up Studies
10
2026
5476
0.300
 Why?
Survival Rate
8
2026
2110
0.300
 Why?
Antibodies, Monoclonal
7
2026
1514
0.290
 Why?
Glioblastoma
1
2012
354
0.280
 Why?
Leukemia
1
2010
247
0.270
 Why?
Young Adult
15
2026
14437
0.270
 Why?
DNA Damage
1
2010
440
0.260
 Why?
Male
31
2026
73950
0.250
 Why?
Infant
14
2026
10194
0.240
 Why?
Female
31
2026
80076
0.240
 Why?
Leukemia, Myeloid, Acute
3
2025
700
0.230
 Why?
Trastuzumab
1
2026
119
0.230
 Why?
Medical Oncology
2
2024
344
0.220
 Why?
Infratentorial Neoplasms
1
2026
71
0.220
 Why?
Liver Neoplasms
1
2012
787
0.220
 Why?
Gene Expression Profiling
1
2012
1794
0.220
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
299
0.220
 Why?
Camptothecin
2
2017
138
0.220
 Why?
Cyclin D
1
2024
8
0.210
 Why?
Cyclin-Dependent Kinases
1
2025
122
0.210
 Why?
Glycogen Synthase Kinase 3 beta
1
2024
74
0.200
 Why?
Dose-Response Relationship, Drug
5
2025
2030
0.200
 Why?
TOR Serine-Threonine Kinases
3
2024
456
0.200
 Why?
Ependymoma
1
2026
179
0.200
 Why?
Neoplasm Staging
3
2024
1492
0.200
 Why?
Bone Neoplasms
2
2024
272
0.200
 Why?
Carcinoma, Non-Small-Cell Lung
2
2023
1195
0.200
 Why?
Sirolimus
2
2016
283
0.190
 Why?
Oncogene Proteins, Fusion
1
2024
212
0.180
 Why?
High-Throughput Nucleotide Sequencing
2
2023
539
0.180
 Why?
Osteosarcoma
1
2023
100
0.180
 Why?
Pediatrics
2
2020
1139
0.180
 Why?
Proto-Oncogene Proteins c-akt
1
2024
440
0.170
 Why?
Topotecan
3
2026
17
0.170
 Why?
Adult
17
2026
41405
0.170
 Why?
Central Nervous System
1
2024
282
0.170
 Why?
Phosphatidylinositol 3-Kinases
1
2023
383
0.160
 Why?
Whole Genome Sequencing
1
2021
183
0.160
 Why?
Salvage Therapy
2
2019
166
0.160
 Why?
Necrosis
2
2019
245
0.160
 Why?
Receptor, IGF Type 1
2
2010
64
0.150
 Why?
Pyridazines
1
2020
57
0.150
 Why?
Lung Neoplasms
2
2023
2679
0.150
 Why?
Dexamethasone
2
2019
368
0.140
 Why?
Etoposide
3
2017
169
0.140
 Why?
Imidazoles
1
2020
247
0.140
 Why?
Combined Modality Therapy
2
2020
1281
0.130
 Why?
Taxoids
1
2018
116
0.130
 Why?
Lymphoma
1
2019
253
0.130
 Why?
B7-H1 Antigen
1
2019
246
0.130
 Why?
Induction Chemotherapy
1
2017
88
0.130
 Why?
Heterocyclic Compounds
1
2017
23
0.130
 Why?
Antineoplastic Agents, Phytogenic
1
2018
178
0.120
 Why?
Cetuximab
1
2017
111
0.120
 Why?
Incidence
1
2024
2954
0.120
 Why?
Glucocorticoids
2
2019
537
0.120
 Why?
Azacitidine
1
2017
168
0.120
 Why?
Cytarabine
3
2025
66
0.120
 Why?
Hematopoietic Stem Cell Transplantation
1
2022
703
0.110
 Why?
Clinical Trials as Topic
3
2025
1072
0.110
 Why?
Retrospective Studies
6
2026
17560
0.110
 Why?
Myelodysplastic Syndromes
1
2017
170
0.110
 Why?
Cyclophosphamide
2
2026
277
0.110
 Why?
Feasibility Studies
1
2019
1147
0.110
 Why?
Treatment Outcome
9
2025
11947
0.110
 Why?
Thyroxine
1
2014
67
0.100
 Why?
Hypothyroidism
1
2014
68
0.100
 Why?
Pilot Projects
1
2019
1912
0.100
 Why?
Arsenicals
1
2013
28
0.090
 Why?
Oxides
1
2013
47
0.090
 Why?
Melanoma
1
2019
774
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
432
0.090
 Why?
Organoplatinum Compounds
1
2012
65
0.090
 Why?
Leucovorin
1
2012
98
0.090
 Why?
In Situ Hybridization, Fluorescence
2
2012
330
0.090
 Why?
DNA Methylation
1
2017
722
0.090
 Why?
Animals
4
2021
38410
0.090
 Why?
Fluorouracil
1
2012
232
0.090
 Why?
Real-Time Polymerase Chain Reaction
1
2012
337
0.080
 Why?
Spinal Cord
1
2014
383
0.080
 Why?
Magnetic Resonance Imaging
3
2019
3980
0.080
 Why?
HL-60 Cells
1
2010
30
0.080
 Why?
Inhibitory Concentration 50
1
2010
91
0.080
 Why?
Oligonucleotide Array Sequence Analysis
1
2012
751
0.080
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2012
980
0.080
 Why?
Antimetabolites, Antineoplastic
1
2010
108
0.080
 Why?
Pyrazoles
2
2025
518
0.080
 Why?
Drug Synergism
1
2010
355
0.080
 Why?
Pons
1
2009
33
0.070
 Why?
Methotrexate
1
2010
235
0.070
 Why?
Vascular Endothelial Growth Factor A
2
2009
552
0.070
 Why?
Brain
2
2014
3009
0.070
 Why?
Polyethylene Glycols
1
2014
649
0.070
 Why?
Recurrence
2
2010
1151
0.070
 Why?
Infant, Newborn
3
2022
6543
0.070
 Why?
Chemistry, Pharmaceutical
1
2008
112
0.070
 Why?
Molecular Targeted Therapy
2
2022
444
0.070
 Why?
Doxorubicin
1
2010
411
0.070
 Why?
Drug Design
1
2008
177
0.060
 Why?
Acute Disease
1
2010
1049
0.060
 Why?
Cell Cycle
1
2010
600
0.060
 Why?
Cell Survival
1
2010
1111
0.060
 Why?
Pyrimidines
2
2023
532
0.060
 Why?
MAP Kinase Signaling System
1
2008
308
0.060
 Why?
Injections, Spinal
1
2026
120
0.060
 Why?
Genomics
2
2022
839
0.060
 Why?
Risk Assessment
1
2015
3784
0.060
 Why?
Cohort Studies
3
2022
6099
0.050
 Why?
Everolimus
1
2025
112
0.050
 Why?
Proto-Oncogene Protein c-fli-1
1
2024
30
0.050
 Why?
RNA-Binding Protein EWS
1
2024
31
0.050
 Why?
United States Food and Drug Administration
1
2025
208
0.050
 Why?
Phenylurea Compounds
1
2025
122
0.050
 Why?
Disease Progression
1
2012
2890
0.050
 Why?
Europe
1
2025
426
0.050
 Why?
RNA, Messenger
1
2012
2812
0.050
 Why?
Mice
1
2021
18491
0.050
 Why?
Immunoconjugates
1
2025
138
0.050
 Why?
Quinolines
1
2025
192
0.050
 Why?
Vincristine
1
2024
148
0.050
 Why?
Lactams
1
2023
28
0.050
 Why?
Radioisotopes
1
2023
37
0.050
 Why?
Infusions, Intravenous
1
2024
430
0.050
 Why?
Cell Proliferation
1
2010
2529
0.050
 Why?
Lactams, Macrocyclic
1
2023
51
0.050
 Why?
Magnesium
1
2023
157
0.050
 Why?
Gene Amplification
1
2023
118
0.050
 Why?
National Cancer Institute (U.S.)
1
2022
55
0.050
 Why?
Aminopyridines
1
2023
129
0.040
 Why?
Oncogenes
1
2022
118
0.040
 Why?
Apoptosis
1
2010
2454
0.040
 Why?
Proto-Oncogene Proteins c-myc
1
2023
169
0.040
 Why?
Microtubule-Associated Proteins
1
2022
197
0.040
 Why?
Models, Biological
1
2008
1772
0.040
 Why?
Drug and Narcotic Control
1
2020
24
0.040
 Why?
Carcinogenesis
1
2022
230
0.040
 Why?
Consensus
1
2022
476
0.040
 Why?
Drug Evaluation, Preclinical
1
2020
196
0.040
 Why?
Immunologic Factors
1
2022
261
0.040
 Why?
United States
3
2025
16313
0.040
 Why?
Fatigue
1
2022
367
0.040
 Why?
Proto-Oncogene Proteins
1
2022
627
0.040
 Why?
Base Sequence
1
2022
2175
0.040
 Why?
Disease Susceptibility
1
2020
347
0.040
 Why?
Retreatment
1
2018
80
0.030
 Why?
Isotretinoin
1
2018
27
0.030
 Why?
Metabolic Clearance Rate
1
2018
115
0.030
 Why?
Hematologic Diseases
1
2018
66
0.030
 Why?
Daunorubicin
1
2017
25
0.030
 Why?
Azepines
1
2018
105
0.030
 Why?
Benzylamines
1
2017
44
0.030
 Why?
Precision Medicine
1
2021
464
0.030
 Why?
Blepharoptosis
1
1997
13
0.030
 Why?
Genes, Dominant
1
1997
100
0.030
 Why?
Treatment Failure
1
2018
360
0.030
 Why?
Disease-Free Survival
1
2019
779
0.030
 Why?
Chromosomes, Human, Pair 1
1
1997
82
0.030
 Why?
Immunotherapy
1
2022
672
0.030
 Why?
Drug Hypersensitivity
1
2018
93
0.030
 Why?
Receptors, CXCR4
1
2017
91
0.030
 Why?
Gastrointestinal Diseases
1
2018
222
0.030
 Why?
Kaplan-Meier Estimate
1
2018
975
0.030
 Why?
Antibiotics, Antineoplastic
1
2016
141
0.030
 Why?
Drug Monitoring
1
2018
402
0.030
 Why?
SEER Program
1
2015
232
0.030
 Why?
Age Factors
1
2020
3372
0.020
 Why?
Genetic Predisposition to Disease
1
2021
2458
0.020
 Why?
Promoter Regions, Genetic
1
2017
1253
0.020
 Why?
Epigenesis, Genetic
1
2017
708
0.020
 Why?
Analysis of Variance
1
2015
1302
0.020
 Why?
Neoplasm Grading
1
2013
313
0.020
 Why?
Prevalence
1
2019
2889
0.020
 Why?
Mutation
1
2023
4130
0.020
 Why?
Radiography
1
2014
862
0.020
 Why?
Signal Transduction
1
2024
5272
0.020
 Why?
Prospective Studies
1
2022
8164
0.020
 Why?
Fatal Outcome
1
2009
306
0.020
 Why?
Tomography, X-Ray Computed
1
2018
2791
0.020
 Why?
Radiosurgery
1
2009
400
0.010
 Why?
Aged
1
2024
26514
0.010
 Why?
Middle Aged
1
2024
36821
0.010
 Why?
Lod Score
1
1997
62
0.010
 Why?
Quality of Life
1
2009
3246
0.010
 Why?
Genetic Markers
1
1997
338
0.010
 Why?
Recombination, Genetic
1
1997
205
0.010
 Why?
Chromosome Mapping
1
1997
512
0.010
 Why?
Pedigree
1
1997
522
0.010
 Why?
Genotype
1
1997
1875
0.010
 Why?
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (237) concept(s)
_
Co-Authors Expand Description
See all (19) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)